Pandemic gives Singapore biotechs a shot in the arm
But young upstarts cannot rely on city-state's small market, say industry players
Add BT as a preferred source
Singapore
IT'S only halfway through 2021, but biotech startups in Singapore have attracted a record amount of capital from venture funds, giving the oft-sidelined sector a fillip amid some tailwinds from the pandemic.
So far, the city-state's biotechs have raised US$360 million, according to Preqin data. This trumps the previous US$65.5 million record raised in 2018 by more than five times (see graph). The year's figures are dominated by larger rounds from Singapore-based startups such as Engine Biosciences, Esco Lifesciences, and Hummingbird Biosciences.
TRENDING NOW
Ohmyhome Ltd sells real estate business for token US$1 due to poor business and continued losses
Buyer for England striker Harry Kane’s former mansion must pay £3.4 million after abandoning deal
Real estate firm Ohmyhome’s journey over the past 10 years
Malaysian tycoon Vincent Tan’s sell-downs point to pruning rather than an exit plan
